Abiraterone acetate is a recently discovered hormonal therapy for adult male patients suffering from prostate cancer. Zytiga 250 mg (Abiraterone acetate) is an oral drug that inhibits the action of proteins (CYP17A1 enzyme) that are responsible for producing a male hormone called testosterone. Abiraterone acetate targets the excessive production of testosterone as prostate cancer cells require these hormones to flourish.